Open AccessValidation of an indigenous assay for rapid molecular detection of rifampicin resistance in presumptive multidrug-resistant pulmonary tuberculosis patients
Author(s) -
N S Gomathi,
Manjula Singh,
V P Myneedu,
D. S. Chauhan,
Srikanth Tripathy,
Rohit Sarin,
Anant Mohan,
Anuj Bhatnagar,
Jiten Singh Khangembam,
T Kannan,
Mohan Rao,
Jyoti Logani,
Bindu Dey,
Raman Gangakhedkar,
Soumya Swaminathan,
Urvashi Singh
Publication year - 2020
Publication title -
indian journal of medical research
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.578
H-Index - 87
ISSN - 0971-5916
DOI - 10.4103/ijmr.ijmr_2557_19
Subject(s) - medicine , genexpert mtb/rif , tuberculosis , sputum , nucleic acid amplification tests , mycobacterium tuberculosis , drug resistance , rifampicin , virology , pathology , microbiology and biotechnology , biology , chlamydia trachomatis
There is a need for an affordable, easy, high-sensitivity test usable at the peripheral health facility for diagnosis of drug-resistant (DR) tuberculosis (TB) to interrupt disease transmission. Nucleic acid amplification tests (NAATs) for early detection of DR-TB are ideal to bring testing near to the patient. Truenat TM MTB (Mycobacterium tuberculosis) and Truenat TM MTB-RIF (rifampicin) is an indigenous chip-based real-time polymerase chain reaction (PCR) based test for detection of multidrug-resistant (MDR) TB. The test involves extraction of DNA using automated, battery operated Trueprep instrument and real-time PCR performed on the Truelab analyzer. We report here multicentric validation of Truenat MTB-RIF for detection of DR-TB in suspected DR-TB patients.